Could $120m Make Editas 1st in Clinic With CRISPR?
This article was originally published in Scrip
Executive Summary
No company working with the genome-editing technology known as CRISPR has taken a therapeutic candidate into the clinic, but Editas Medicine has raised $120m in Series B private financing to refine its platform and prepare its first potential products for human testing.